Nachrichten zur Ligand Pharmaceuticals Inc. Aktie

Palvella Therapeutics Appoints Matthew E. Korenberg as Chief Financial Officer

Mr. Korenberg is a seasoned executive with significant operational and financial leadership experience, including senior roles at Ligand Pharmaceuticals (NASDAQ:…

invIOs raises €8.2 million in a Series A to finance pipeline progress in immuno-oncology

VIENNA, Oct. 15, 2024 (GLOBE NEWSWIRE) -- invIOs GmbH (“invIOs”), a privately held biotechnology company developing novel therapies…

Ligand Pharmaceuticals Incorporated 2024 Q2 - Results - Earnings Call Presentation

…

Ligand Pharmaceuticals reports mixed Q2 results; reaffirms FY24 outlook

…

Ligand Pharmaceuticals: Solid Performer Performing Solidly

…

Ligand (LGND) Beats Q1 Earnings, Misses Sales Estimates

Ligand Pharmaceuticals (LGND) reports mixed first-quarter results. Management reiterates the 2024 financial outlook.…

Ligand Pharmaceuticals Incorporated 2024 Q1 - Results - Earnings Call Presentation

…

Ligand (LGND) Q4 Earnings Surpass Estimates, Stock Surges

Ligand Pharmaceuticals (LGND) reports encouraging fourth-quarter results as earnings and sales beat estimates. Management reiterates the 2024 financial outlook.…

Ligand Pharmaceuticals: A Complicated Tale

…

Ligand Pharmaceuticals Inc. (LGND) Q3 2023 Earnings Call Transcript

…

Ligand (LGND) Beats on Q3 Earnings & Sales, Raises 23 View

Ligand Pharmaceuticals (LGND) reports encouraging third-quarter results as earnings and sales beat estimates. Management raises the 2023 financial outlook.…

Ovid Therapeutics and Ligand Pharmaceuticals Enter into a $30 Million Agreement for a 13% Interest in Soticlestat Royalties and Milestones Extending Ovid’s Cash Runway into 2026

NEW YORK and SAN DIEGO, Oct. 18, 2023 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical…

Ligand Pharmaceuticals CEO Davis Todd increases shareholding

…

Ligand Pharmaceuticals (LGND) Q2 Earnings Beat Estimates

Ligand (LGND) delivered earnings and revenue surprises of 86.84% and 5.85%, respectively, for the quarter ended June 2023. Do the…

Ligand Pharmaceuticals Non-GAAP EPS of $1.42 beats by $0.76, revenue of $26.4M beats by $0.67M

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Ligand Pharmaceuticals Inc Q2 Earnings Summary

WASHINGTON (dpa-AFX) - Below are the earnings highlights for Ligand Pharmaceuticals Inc (LGND):Earnings: $2.29 million in Q2 vs. -$0.90 million…

Bear of the Day: Ligand Pharmaceuticals (LGND)

Ligand is an innovative Bio-Pharma M&A royalty-generator, but the model is volatile...…

Ligand Pharmaceuticals (LGND) Stock Sinks As Market Gains: What You Should Know

Ligand Pharmaceuticals (LGND) closed the most recent trading day at $68.13, moving -0.92% from the previous trading session....…

Ligand (LGND) Offers $15M in Cash to Acquire All Novan Assets

Ligand (LGND) announces a $15 million bid in cash to acquire all assets of Novan Inc. along with another $15…

Ligand Pharmaceuticals (LGND) Outpaces Stock Market Gains: What You Should Know

Ligand Pharmaceuticals (LGND) closed the most recent trading day at $68.76, moving +1.34% from the previous trading session....…

Ligand Makes $15 Mln Acquisition Offer After Novan Files For Bankruptcy Protection

WASHINGTON (dpa-AFX) - Ligand Pharmaceuticals Inc. (LGND) said on Monday that it has made bid to acquire the assets of…

Novan Enters into Agreement to Sell Substantially All of its Assets, including Berdazimer Gel, 10.3% (SB206), and Files for Chapter 11 Protection

– The Company and Ligand Pharmaceuticals sign agreement to sell substantially all of Novans assets under Section 363 of the…

DTx Pharma announces acquisition by Novartis

DTx Pharmas Fatty Acid Ligand Conjugated Oligonucleotide (FALCON™) platform facilitates extra-hepatic delivery of siRNA therapeutics Acquisition includes DTx-1252 with the…

Ligand Pharmaceuticals (LGND) Stock Sinks As Market Gains: What You Should Know

Ligand Pharmaceuticals (LGND) closed the most recent trading day at $69.49, moving -0.52% from the previous trading session....…

Press Release: Positive topline Phase 2b data in atopic dermatitis support amlitelimab as a potential first and best-in-class novel investigational anti-OX40-ligand monoclonal antibody

Um den gesamten Artikel unter globenewswire.com zu lesen, klicken Sie bitte auf die Überschrift...…

Is GSK PLC Sponsored ADR (GSK) Stock Outpacing Its Medical Peers This Year?

Here is how GSK (GSK) and Ligand Pharmaceuticals (LGND) have performed compared to their sector so far this year....…

Wall Street Analysts See a 44.32% Upside in Ligand (LGND): Can the Stock Really Move This High?

The consensus price target hints at a 44.3% upside potential for Ligand (LGND). While empirical research shows that this sought-after…

Form 8-K LIGAND PHARMACEUTICALS For: Jun 09

Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…

Is Ligand Pharmaceuticals (LGND) Stock Outpacing Its Medical Peers This Year?

Here is how Ligand Pharmaceuticals (LGND) and Clover Health Investments, Corp. (CLOV) have performed compared to their sector so far…

Arvinas Announces Interim Data from the ARV-766 Phase 1/2 Dose Escalation and Expansion Trial Showing Promising Signals of Efficacy in Late-line mCRPC, Including in Patients with AR L702H Mutations

– 42% of patients with AR ligand binding domain (LBD) mutations achieved PSA50; in patients with AR L702H mutations, 3…

Wall Street Analysts Think Ligand (LGND) Could Surge 44.42%: Read This Before Placing a Bet

The mean of analysts price targets for Ligand (LGND) points to a 44.4% upside in the stock. While this highly…

Insiderhandel: Aufsichtsrat verkauft Aktien von Ligand Pharmaceuticals im Wert von 343.081$

Kozarich, John W. - Aufsichtsrat - Tag der Transaktion: 2023-05-16...…

Insiderhandel: Aufsichtsrat verkauft Aktien von Ligand Pharmaceuticals im Wert von 490.628$

Kozarich, John W. - Aufsichtsrat - Tag der Transaktion: 2023-05-08...…

Recap: Ligand Pharmaceuticals Q1 Earnings

Ligand Pharma up 5% after hours on 2023 guidance boosts

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Ligand Pharmaceuticals Inc Q1 Earnings Summary

WASHINGTON (dpa-AFX) - Below are the earnings highlights for Ligand Pharmaceuticals Inc (LGND):Earnings: $41.95 million in Q1 vs. -$15.39 million…

2 Medical Stocks to Buy Before Earnings

Cardinal Health (CAH) and Ligand Pharmaceuticals (LGND) are two healthcare companies that investors certainly want to watch going into their…

Harpoon Therapeutics Presents Preclinical Results for Novel T Cell Engagers HPN217 and HPN328 at AACR 2023

SOUTH SAN FRANCISCO, Calif., April 18, 2023 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (Nasdaq: HARP), a clinical-stage immuno-oncology company…

Insiderhandel: Vorstand verkauft Aktien von Ligand Pharmaceuticals im Wert von 20.977$

Reardon, Andrew - Vorstand - Tag der Transaktion: 2023-03-24...…

Zacks Industry Outlook Highlights CRISPR Therapeutics, Ligand Pharmaceuticals, Theseus Pharmaceuticals and Kala Pharmaceuticals

CRISPR Therapeutics, Ligand Pharmaceuticals, Theseus Pharmaceuticals and Kala Pharmaceuticals are part of the Zacks Industry Outlook article....…

How Much Upside is Left in Ligand (LGND)? Wall Street Analysts Think 49.11%

The average of price targets set by Wall Street analysts indicates a potential upside of 49.1% in Ligand (LGND). While…

Form 8-K LIGAND PHARMACEUTICALS For: Mar 13

Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…

Ligand Pharmaceuticals (LGND) Surpasses Q4 Earnings and Revenue Estimates

Ligand (LGND) delivered earnings and revenue surprises of 10.57% and 24.42%, respectively, for the quarter ended December 2022. Do the…

Ligand Pharmaceuticals Inc Q4 Earnings Summary

WASHINGTON (dpa-AFX) - Below are the earnings highlights for Ligand Pharmaceuticals Inc (LGND):Earnings: -$17.49 million in Q4 vs. -$5.42 million…

Form 8-K LIGAND PHARMACEUTICALS For: Feb 22

Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…

Allogene Therapeutics Publishes Preclinical Data in Clinical Cancer Research Supporting DLL3 as a Potential AlloCAR T™ Target for Small Cell Lung Cancer

SOUTH SAN FRANCISCO, Calif., Jan. 25, 2023 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company…

dpa-AFX ProFeed